Taking advantage of the longitudinal design of the NSHDS, we found that the pre‐diagnostic plasma levels for sVEGFR2, sTNFR2, sIL‐2Rα and sIL‐6R were associated with glioma risk, a finding that suggests these proteins might play a role in glioma development. Here, IL6R is linked to glioma.